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ABSTRACT  The antigenic site recognized by a rat monoclonal antibody (clone YL 1/2) reacting 
with a-tubulin (Kilmartin, J. V., B. Wright, and C. Milstein, 1982,  I. Cell Biol., 93:576-582)  has 
been determined  and partially characterized. YL 1/2 reacts specifically with the tyrosylated 
form  of brain a-tubulin from different  mammalian species. YL 1/2 reacts with the synthetic 
peptide Gly-(Glu)3-Gly-(Glu)2-Tyr, corresponding to the carboxyterminal amino acid sequence 
of tyrosylated t~-tubulin, but does not react with Gly-(Glu)3-Gly-(Glu)2, the constituent peptide 
of detyrosylated a-tubulin. Electron microscopy as well as direct and indirect immunofluores- 
cence microscopy shows that YL 1/2 binds to the surface of microtubules polymerized in vitro 
and in vivo.  Further in vitro studies show that the antibody has no effect  on the rate and 
extent of microtubule  polymerization,  the stability of microtubules, and the incorporation  of 
the microtubule-associated  proteins (MAP2) and tau into microtubules.  In vivo studies using 
Swiss 3T3 fibroblasts injected with YL 1/2 show that, when injected at low concentration  (2 
mg IgG/ml  in the injection  solution), the antibody binds to microtubules  without changing 
their distribution  in the cytoplasm. Injection of larger concentration  of YL 1/2 (6 mg IgG/ml) 
induces  the  formation  of  microtubule  bundles,  and  still higher  concentrations  cause the 
aggregation of microtubule  bundles around the nucleus (>12 mg IgG/ml). 
The conditions for microtubule polymerization in vitro are 
known in great detail. Microtubule assembly in vitro requires 
physiological temperature, ionic strength (0.1-0.14 M),  pH 
6.7-7.0, guanosine triphosphate (1 mM), Mg  ÷÷ (1 mM) (33), 
and is greatly enhanced by a set of proteins called MAW (i.e., 
microtubule-associated proteins; 8,  14,  32).  In contrast the 
chemical mechanisms actually involved in the assembly of 
microtubules in vivo and in vitro are poorly understood. 
Phosphorylation of MAP (7, 25) and the binding of Ca  +÷- 
J Abbreviations  used  in  this  paper:  MES, 2-(N-morpholino)eth- 
anesulfonic acid; PMSF, phenylmethylsuifonyi  fluoride; and MAP, 
microtubule-associated  proteins. 
calmodulin (12) to  microtubules have been shown respec- 
tively to inhibit polymerization (7) and to promote depolym- 
erization (12) of microtubules in vitro, but it is not known 
whether they are relevant in vivo. Although the posttransla- 
tional modification of proteins is an important device in the 
regulation of protein function, nothing is known about the 
role played by the phosphorylation of B-tubulin (3, 21) and 
the detyrosylation of  a-tubulin (28) in the polymerization and 
function of microtubules in vivo. With respect to the removal 
and incorporation of tyrosine into the carboxyterminus of a- 
tubulin, it would be important to locate this part of  the tubulin 
molecule in the microtubule and to determine whether or not 
it is involved in the assembly and function of microtubules. 
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body  that specifically recognizes the tyrosylated  form  of a- 
tubulin. By using this antibody we have found the following: 
that the tyrosylated  carboxyterminus of a-tubulin  is (a) ex- 
posed on the surface of microtubules assembled in vitro and 
of cytoplasmic,  spindle,  and midbody  microtubules polym- 
erized in  vivo,  is (b)  not  involved in the polymerization  of 
tubulin into microtubules, is (c) not part of the domains of 
tubulin  binding  MAP2  and  tau,  and  (d)  could  play  a  yet 
unknown role in the normal distribution and organization of 
microtubules in the cytoplasm of interphase cells and in their 
function (32).  Portions of this work  have been presented in 
abstract form (31). 
MATERIALS  AND  METHODS 
Purification of Microtubule Protein and Studies on Micro- 
tubules Polymerized In Vitro:  Pig and rat brain microtubule protein 
were purified by two cycles of  temperature-dependent polymerization-depolym- 
erization (24) using buffer A (0.1 M MES, l mM MgCl2, 0.1 mM EGTA,  1 
mM B-mercaptoethanol, l mM guanosine triphosphate, 0.2 mM phenylmeth- 
ylsulfonyl fluoride, pH 6.75), and adding  30% glycerol in the first cycle of 
polymerization. Homogeneous tubulin,  MAPs, and tau were prepared from 
microtubule protein as described (8, 22). 
All purified proteins were stored under liquid nitrogen. Studies on micro- 
tubule polymerization in vitro were performed using solutions of microtubule 
protein prepared in buffer A without pbenylmethyisulfonyl fluoride. Polymer- 
ization was induced  by raising the temperature  of the microtubule  protein 
solution from 4"C to 37"C. The time course of microtubule polymerization was 
studied by continuously  reading the turbidity  developed at 350 nm using a 
Cary 15 spectrophotometer. The content of MAP2 and tau in microtubules was 
studied by measuring the MAPs and tau contained  in microtubule  pellets 
obtained from steady state microtubules polymerized using microtubule pro- 
tein. Protein concentrations were estimated on SDS polyacrylamide gels using 
a microdensitometer (Joyce Loeble 3CS). The incorporation of MAP2 and tau 
into steady state microtubules polymerized using homogeneous tubulin was 
studied in a similar way (23). The effects of the monoclonal YL 1/2 a-tubulin 
antibody on microtubule polymerization and stability, the content of MAPs 
and tau in microtubules, and binding of MAP2 and tau to microtubules were 
studied by preincubating different concentrations of antibody (see Results) with 
microtubule protein or purified tubulin at 4"C for 45 min before incubation at 
37"C for 45 min or by polymerizing microtubule protein or purified tubulin to 
steady state for 45 min at 37"C before adding the antibody for another 45 min 
at 37"C. 
Antibodies:  The rat monoclonal  YL  1/2 and YOL  1/34  a-tubulin 
antibodies used in our studies were a gift of Dr. Kilmartin (Medical Research 
Council, Cambridge). Affinity-purified rat brain tubulin antibodies were ob- 
tained  as previously described (36). Rhodamine-conjugated  goat anti-rabbit 
IgGs as well as rhodamine-  and fluoresceine-conjugated goat anti-rat  IgGs 
(Cappel Laboratories, Cochranville, PA) were purified by affinity chromatog- 
raphy  using respectively rabbit IgG and rat  lgG coupled  to Sepharose 4B 
columns. Rhodamine-conjugated YL 1/2 antibodies containing 2 mol rhoda- 
mine/mole antibody were prepared using tetramethylrhodamine isothiocyanate 
as described (16). Cleavage of YL  1/2 antibodies  into Fab-fragments with 
mercuripapain  (Worthington  Biomedical) was performed  as described (18) 
using a ratio of enzyme to IgG (wt/wt) of 1:600. Digestion was performed at 
37"C for  l  h with an lgG concentration  of 2 mg/ml,  and cleavage products 
were separated on a Sephacryl S-300 column. 
Antibody Probes:  Approximately 15% of the total a-tubulin purified 
from brain is normally tyrosylated (17), detyrosylated bovine brain microtubule 
protein was a gift of Dr. Kumar (National Institutes of Health) and was prepared 
as previously described (13) by treatment ofmicrotubule protein with pancreatic 
carboxypeptidase A. The octapeptide Gly-(Glu)3-Gly-(Glu)2-Tyr  and the hep- 
tapeptide Gly-(Glu)3-Gly-(Gluh, constituents of the tyrosylated and detyrosy- 
lated carboxyterminus of a-tubulin,  were synthesized by Penninsula Labora- 
tories, Inc. (Belmont, CA) and were 69% (octapeptide) and 83% (heptapeptide) 
pure when examined by amino acid analysis. 
Antibody-binding Studies:  Immunoautoradiography oftyrosylated 
and detyrosylated brain microtubule protein resolved into the a- and ~-tubulin 
subunits by SDS PAGE was performed as previously described (5) using YL 1/ 
2 and YOL  1/34 as first antibodies and usI-iodinated purified rabbit anti-rat 
IgGs as second antibodies. 
Indirect Immunofluorescence Microscopy, Electron Micros- 
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copy, and Microinjection Studies:  Swiss  3T3 fibroblasts  were  grown 
in Dulbecco's modified Eagle medium containing  10% fetal calf serum. PtK2 
cells (rat kangaroo) were grown in HAM's FI2 medium containing 5% fetal 
calf serum.  All cells were grown  for  2  d  before being  used. Microtubule 
cytoskeletons of PtK2 cells grown on coverslips were prepared as follows at 
room  temperature.  The cells were briefly washed with 0.1  M  MES,  l  mM 
MgCI2,  1 mM EGTA, 4% polyethylenglycol 6000, pH 6.75 (buffer B), then 
extracted for 30 s with buffer B containing 0.2% Triton  X-100, washed with 
buffer B, fixed with buffer B containing 2% glutaraldehyde for  15 min, and 
washed with PBS. The fixed cytoskeletons were fnally treated with 1 mg/ml 
NaBH4 in PBS as described (29). For specific removal of carboxyterminal 
tyrosine from a-tubulin the cytoskeletons were incubated with 10 gg/ml pan- 
creatic carboxypeptidase A (Worthington  Biomedical) in PBS for 30 min at 
37"C and washed three times with PBS. Microinjection and indirect immuno- 
fluorescence microscopy were performed by procedures already described (30) 
using a Zeiss ICM 405 microscope. Cells were normally fixed and permeabilized 
with cold methanol  (-20"C) for 5 min. For electron microscopy cells were 
grown in plastic dishes, fixed, and embedded in situ, and processed as previously 
described (35). 
For preabsorption experiments using indirect immunofluorescence micros- 
copy, the peptides  Gly-(Glu)rGly-(Glu)s  or Gly-(Glu)3-Gly-(Glu)2-Tyr  and 
either YL  I/2 or YOL  1/34 antibodies were mixed in 0.1 M MES, pH 6.75, 
containing 10 mg/ml BSA at final concentrations of 10 #g lgG/ml and 0.5 mg 
peptide/ml.  After being kept for 20 min at room temperature,  20 ul of each 
mixture were added to PtK2 cytoskeletons on circular  18-mm coverslips and 
indirect immunofluorescence microscopy was performed as described above. 
RESULTS 
Monoclonal YL I/2 Antibody Reacting with a- 
Tubulin Specifically Recognizes  the Tyrosylated 
Form of the Protein 
Two rat monoclonal antibodies (clones YL  1/2 and YOL 
1/34) raised against yeast tubulin were shown to react specif- 
ically with  a-tubulin (9).  In the cell  a-tubulin exists in  two 
different forms, tyrosylated and detyrosylated (2,  15,  17,  19; 
see also reference 26), a-tubulin is translated as the tyrosylated 
form (28). 
Detyrosylation is performed by a  specific carboxypeptidase 
that removes tyrosine from the carboxyterminus of the protein 
(1, 6,  10, 27; see also reference  13). The removed tyrosine is 
put  back  into  the  protein  by  the  enzyme  tubulin  tyrosine 
ligase in a  reaction requiring ATP (20; see also reference 4). 
Immunoautoradiography  of bovine brain  microtubule  pro- 
tein containing either tyrosylated or detyrosylated  a-tubulin 
showed that the YL  1/2 antibody reacted exclusively with the 
tyrosylated form of a-tubulin (Fig.  1, compare lanes 5 and 6). 
On  the  other  hand  YOL  1/34  antibody  reacted  with  both 
tyrosylated and detyrosylated  a-tubulin (Fig.  1,  lanes 3  and 
4). 
Studies on the Effects of YL 1[2 on Microtubule 
Polymerization  and the Incorporation of MAP2 
and Tau into Microtubules Assembled In Vitro 
Microtubule polymerization resulted from the longitudinal 
and lateral association of tubulin  molecules. Although both 
tyrosylated  and  detyrosylated  a-tubulin  displayed  identical 
abilities to polymerize in vitro (19), it was not known whether 
the carboxyterminus of a-tubulin was involved in the associ- 
ation of tubulin molecules needed for the polymerization of 
tubulin into  microtubules.  The  specific  reaction  of YL  1/2 
with  the  tyrosylated  carboxyterminus  of a-tubulin  made  it 
possible to study the involvement of this part of a-tubulin in 
the  polymerization  of tubulin  into  microtubules.  For  this 
purpose we studied the time course of microtubule polymer- 
ization in the presence and absence of YL  1/2. 
As shown  in  Fig.  2A,  the lag time preceding the  start  of FIGURE  1  Immunoautoradiog- 
raphy of tyrosylated and detyro- 
sylated  brain tubulin run on SDS 
polyacrylamide  gels  and  incu- 
bated with YL 1/2 and YOL 1/34 
antibodies. 50 #g of detyrosylated 
bovine brain tubulin (lanes 1, 3, 
and 5) and 0.1  ug of tyrosylated 
rat brain tubulin (lanes 2, 4, and 
6) were run on a 10% SDS poly- 
acrylamide slab gel. The gel was 
cut in three parts. One part was 
stained  with  Coomassie  Blue 
(lanes 1 and 2) and the other two 
incubated with YOL 1/34 (lanes 3 
and 4) and YL 1/2 (lanes 5 and 6) 
for immunoautoradiography (see 
Materials and Methods).  Observe that the small amount of tyrosyl- 
ated tubulin sampled  on lanes 2, 4,  and  6 was not detected by 
Coomassie Blue staining (see lane 2). Note the specific  reaction of 
YL 1/2 with the tyrosylated form of ~-tubulin (compare lanes 5 and 
6) and the binding of YOL 1/34 to both tyrosylated and detyrosy- 
lated o~-tubulin (compare lanes 3 and 4). 7, tubulin. 
37"C,  and  of (b) steady state  microtubules incubated with 
different concentrations of antibody at 37"C. The results of 
the sedimentation assay shown in Fig. 2 B demonstrated that 
tubulin polymerization was identical in preparations of mi- 
crotubule protein preincubated with or without YL  1/2 at 
4"C for 45 min before polymerization at 37"C. These results 
indicated  that  the  antibody  had  no  effect on  the  rate  of 
microtubule  nucleation  and  therefore that  the  tyrosylated 
carboxyterminus of a-tubulin was  not required for the for- 
mation of microtubule nuclei. Studies on both the rate and 
extent of turbidity developed during microtubule polymeri- 
zation revealed slight increases in samples incubated with the 
antibody. The increase was larger at higher concentrations of 
YL 1/2 (Fig. 2A). Because no differences  in the critical tubulin 
concentration for polymerization were found between prep- 
arations of microtubule protein polymerized in the presence 
and absence of YL  1/2 (data not shown; see Fig.  2B), the 
increases of the rate and extent of turbidity in the presence of 
YL  1/2  were probably due  to  coating of microtubules by 
antibody (see  Fig.  3 b).  When microtubules polymerized in 
the presence and absence of antibody were cooled at 4"C, the 
turbidity decreased with  identical  rates to the  initial  basal 
levels (data not shown). 
This result  indicated that  the  antibody did  not stabilize 
microtubules against cooling. Furthermore, microtubules po- 
lymerized in the absence and presence of YL 1/2 contained 
comparable amounts of MAP2 and tau (Fig. 2 B), suggesting 
that the two MAP do not bind to the tyrosylated carboxyter- 
minus of a-tubulin exposed on the surface of  the microtubules 
(see below). 
Location of the Tyrosylated Carboxyterminus  of 
o~-Tubulin in Microtubules  Polymerized In Vitro 
and In  Vivo 
To study the location of the tyrosylated carboxyterminus 
of a-tubulin in microtubules, we looked to the ability of YL 
1/2 to bind to tubulin in microtubules polymerized both in 
vitro and in vivo. 
We studied the  ability of YL  1/2  to bind to  tubulin  in 
microtubules polymerized in vitro by measuring the antibody 
content of microtubule pellets obtained from preparations of 
(a) microtubule protein incubated with different concentra- 
tions of antibody at  4"C before raising the temperature to 
WEHLAND  ET  AL. 
FIGURE 2  (A) Time course of microtubule polymerization in vitro 
in the absence and presence of YL 112 antibody. Rat brain micro- 
tubule protein was prepared in buffer A at  1 mg/ml and  preincu- 
bated in the absence (a) and presence (b-e) of different concentra- 
tions of YL  1/2  for 45  min  at  4°C.  The molar ratios  of tubulin/ 
antibody used were 2.5  (b), 1.25 (c), 0.6  (d), and 0.125  (e). Po- 
lymerization was started  by raising the temperature to 37°C. Ob- 
serve  the  similar  polymerization lags of  the  samples  incubated 
without  and  with  different  concentrations of  YL  1/2.  Note  the 
increase  in  the  rate  and  total  extent of turbidity  developed in 
samples incubated with  increasing  concentrations of YL  1/2.  (B) 
MAP2 and tau content of microtubules polymerized in vitro in the 
absence and presence of YL 1/2. Rat brain microtubule protein (1 
mg/ml in buffer A) was incubated without and with different con- 
centrations  of YL 1/2 for 45 min at 4°C before polymerization for 
45  min  at  37°C.  The  microtubules  formed  were  collected  by 
centrifugation using a Beckman Airfuge (20 psi for 20 min) and their 
protein content analyzed on a  12% SDS polyacrylamide slab gel 
(lanes  1-4). The protein contained in  the corresponding sample 
supernatants was similarly  studied (lanes 5-8). Sample incubated 
without YL 1/2 (lanes 1 and 5), and samples incubated with a molar 
ratio of tubulin/antibody of 2 (lanes 2 and 6), 1 (lanes 3 and 7), and 
0.2  (lanes 4 and 8).  LC,  IgG-light chain; HC,  IgG-heavy  chain; T, 
tubulin. 
A Monoclonal  Antibody  Specific  for Tyrosylated  ~-Tubulin  1469 FIGURE 3  Longitudinal and  cross  section  views of  microtubules 
polymerized  in  the  absence  or  presence  of  YL  112.  (a  and  c) 
Microtubules polymerized in the absence of antibody (correspond- 
ing to sample shown in Fig. 2B, lane  1). Note the arm-like projec- 
tions of the microtubule walls. (b and d) Microtubules polymerized 
in the presence  of YL 1/2 (corresponding to the sample shown in 
Fig. 2B, lane 4). Observe the uniform antibody-coating of microtu- 
bules (compare  a and  b) and the frequent  presence  of doublets 
and triplets of microtubules in the samples of microtubule protein 
polymerized in the presence of YL 1/2 (arrows in d). Bar, 0.1 p.m. x 
88,000. 
YL  1/2  was  able  to  bind  to  tubulin  in  a  concentration- 
dependent manner without affecting polymerization. Electron 
microscopy studies of microtubule pellets showed no aberrant 
polymerization and furthermore antibody coating of the mi- 
crotubules polymerized in the presence of YL  1/2 (Fig.  3). 
Identical results were obtained when steady state microtubules 
were incubated with different concentrations of antibody (not 
shown). These results indicated that the tyrosylated carboxy- 
terminus of a-tubulin was located on the surface of microtu- 
bules polymerized in vitro. 
Indirect immunofluorescence microscopy studies using YL 
1/2 showed that the tyrosylated carboxyterminus of a-tubulin 
was also located on the surface of cytoplasmic, midbody (Fig. 
4,b and c'), and spindle microtubules (data not shown) as 
shown by the fluorescent labeling of these microtubules in 
cytoskeletons incubated with YL 1/2. The binding of YL 1/ 
2  to  the  microtubules  of cultured cells  was  prevented by 
preincubating the antibody with the synthetic peptide Gly- 
(Glu)3-Gly-(Glu)2-Tyr but  not  by preincubation with  Gly- 
(Glu)3-Gly-(Glu)2  (data  not  shown).  Gly-(Glu)3-Gly-(Glu)2- 
Tyr corresponds to the sequence of the eight last amino acids 
of  the carboxyterminus of tyrosylated a-tubulin (17, 28). Gly- 
(Glu)3-Gly-(Gluh is  constituent of the  carboxyterminus of 
detyrosylated a-tubulin. Neither peptide affected labeling of 
microtubules when  preincubated with  YOL  1/34.  Further- 
more the binding of YL  1/2 to microtubules was abolished 
by treating microtubule cytoskeletons with carboxypeptidase 
A (Fig. 4e'), an enzyme which selectively removed carboxy- 
terminal tyrosine from a-tubulin (19). As expected treatment 
of cytoskeletons with carboxypeptidase A did not affect the 
binding of YOL  1/34  (Fig.  4f')  or the  polyclonal tubulin 
antibody (Fig.  4,  e and f) to microtubules. Comparison of 
labeled microtubules using a  mixture of YL  1/2 and poly- 
clonal tubulin antibody as first antibodies in indirect immu- 
nofluorescence studies revealed identical numbers and pat- 
terns of microtubule distribution (Fig. 4, compare a and b). 
Effects of the Injection of YL 1/2 into Swiss 3T3 
Fibroblasts on the Organization of Cytoplasmic 
Microtubules 
Swiss 3T3 flbroblasts displayed microtubules stretching ra- 
dially from the perinuclear centrosome to the plasma mem- 
brane (see uninjected cells in  Fig.  5,  b and  e). Injection of 
rhodamine-conjugated YL  1/2 into cells at a concentration 
FIGURE 4  Double immunofluorescence microscopy of microtubule cytoskeletons  prepared  from PtK2 cells. Cytoskeletons  were 
prepared  as described in Materials  and Methods. Microtubules were studied by double immunofluorescence microscopy using 
mixtures  of  antibodies  recognizing different  tubulin antigenic  determinants.  The  first  antibody  mixture  consisted  of  rabbit 
polyclonal tubulin antibody mixed with either YL  1/2 or YOL  1134 antibody. The second  antibody consisted  of a  mixture of 
fluorescein-conjugated goat anti-rat IgG and rhodamine-conjugated goat anti-rabbit IgG. Binding of the polyclonal antibody to 
microtubules was studied with optics selective for rhodamine, binding of the monoclonal YL 112 and YOL  1134 antibodies to 
microtubules was studied with optics selective for fluorescein. (a, b, c, c', d, and d') Display of microtubules in cells studied by 
double immunofluorescence using either mixtures of polyclonal and YL 112 antibodies (a, b, c, and c') or mixtures of polyclonal 
and YOL 1134 antibodies (d and d'). (a and b) Detail of a cytoskeleton studied using polyclonal (a) and YL 112 (b) antibodies. (c") 
Corresponding phase contrast to cytoskeletons in c and c'.  (d")  Corresponding phase contrast to cytoskeletons  in d and d'. 
Observe that microtubule patterns  revealed  by the polyclonal and the YL 1/2 antibodies are identical (compare  a with b and c 
with c'), as well as microtubule patterns  revealed  by polyclonal and YOL 1/34 antibodies (compare  d with d'). Note the labeling 
of microtubules in the intracellular bridge by polyclonal and YL 1/2 antibodies (compare  c with c').  (e, e', f, and f')  Effect of 
treatment of the microtubule cytoskeleton with pancreatic carboxypeptidase A on the ability of the polyclonal (e and f), YL 112 
(e'), and YOL 1/34 (f') antibodies to bind to microtubules. (e" and f") Corresponding phase contrast  to cytoskeletons  in e and 
e' and f and f',  respectively. Observe that treatment of the microtubule cytoskeletons  with carboxypeptidase A abolished the 
binding of YL 1/2 to microtubules (e'), but has no effect on the binding of the polyclonal (e and f) and YOL 1/34 (f') antibodies 
to microtubules. Bars, 20/~m.  (a and b) x  1,250. (c-f") x  250. 
1470  THE  JOURNAL OF  CELL BIOLOGY • VOLUME 97,  1983 W[HLAND  ET  AL.  A Monoclonal Antibody Specific for Tyrosylated  a~-  Tubulin  1471 FIGURE 5  Effect of the intracellular injection of YL 1/2 and YOL 1/34 on the distribution of microtubules in the cytoplasm of 
Swiss 3T3 fibroblasts.  (a-e)  Double immunofluorescence of cells injected with unconjugated YL 1/2 (a) or unconjugated YOL 1/ 
34 (d) with ~12 mg IgG/ml in the injection solution. (c) Corresponding phase contrast  of cells in a and 6. 3 h after the injection, 
the cells  were fixed and  processed  for indirect immunofluorescence using  polyclonal rabbit tubulin antibody followed  by a 
mixture of fluorescein-conjugated goat anti-rat IgG and rhodamine-conjugated goat anti-rabbit IgG as second antibody. Cells in 
a and d were viewed with optics selective for fluorescein to study the distribution of YL 1/2 (a) and YOL 1/34  (d) injected into 
the cells. The same fields were viewed with optics selective for rhodamine (b and e) to study the distribution of microtubules in 
both uninjected and injected cells. Note the aggregation of microtubule bundles around the nucleus of the cell injected with YL 
1/2 (a and b) but diffuse distribution of injected YOL 1/34  (d) without affecting the normal distribution of microtubules in the 
same cell (e). (f, g, and h) Direct immunofluorescence of cells injected with rhodamine-conjugated YL 1/2. Cells were injected 
with ~12 mg IgG/ml (f), 6 mg IgG/ml (g), 2 mg IgG/ml (h) of rhodamine-conjugated YL 1/2 in the injection solution and 3 h later 
fixed with 3% formaldehyde for 10 min. Note the normal microtubule distribution in the cell injected with the lowest concentration 
of YL 1/2 (h) and the formation of microtubule bundles in the cells  injected with the two higher concentrations of antibody (f 
and g). Observe the higher capacity of unconjugated YL 1/2 compared to rhodamine-conjugated YL 1/2 to induce the aggregation 
of microtubule bundles (compare  a with f). Bars, 20 p.m; (a, b, and g) x  500. (d, e, and f) x  400. 
1472  THE JOURNAL OF  CELL BIOLOGY • VOLUME 97,  1983 FIGURE 6  Electron microscopy of Swiss 3T3 fibroblasts  injected with YL 1]2. Cells were injected with unconjugated YL 1/2 with 
~6 mg IgG/ml in the injection solution and after 3 hr processed for electron microscopy.  (A) Low magnification of the periphery 
of an injected cell with numerous microtubule bundles (arrowheads in A). (B) Higher magnification of inset in A. Longitudinal (C) 
and cross sections (D) of microtubule bundles at high magnification to show regular alignment of microtubules (arrows in C and 
arrowheads in D) in antibody-induced bundles.  Bars, (A and B) 1 /~m; (C and D) 0.1 /~m. (A) x  12,000. (B) x  22,500. (C and D) 
x  75,000. of 2 mg IgG/ml in the injection solution resulted in binding 
of the antibody to microtubules without changing the distri- 
bution of microtubules in the cytoplasm (Fig.  5 h). Injection 
of larger concentrations  of rhodamine-conjugated  YL  1/2 
resulted in formation of microtubule bundles (6-12 mg IgG/ 
ml  in  the  injection  solution;  Fig.  5,  g  and f).  Although 
unconjugated YL 1/2, when injected at low concentration (2 
mg/ml), did not affect the normal distribution  of microtu- 
bules in the cytoplasm by binding to microtubules (data not 
shown), unconjugated YL 1/2 at higher concentrations was 
more effective than  rhodamine-conjugated YL  1/2  in pro- 
moting the aggregation of microtubule bundles around the 
nucleus (in Fig. 5, compare a withfand g). On the other hand 
injected Fab-fragments of YL 1/2 remained diffusely distrib- 
uted in the cytoplasm (data not shown), even when injected 
at high concentrations (10 mg/ml in the injection solution), 
i.e., microtubules were not decorated and their normal distri- 
bution remained unaffected when examined by double im- 
munofluorescence. Even though Fab-fragments bound to mi- 
crotubules when examined by indirect immunofluorescence 
(not  shown),  nonreactivity of microinjected  Fab-fragments 
with microtubules might be due to a decreased affinity often 
found  for  Fab-fragments prepared  from  monoclonal  anti- 
bodies. 
After injection of YL  1/2 at intermediate concentrations 
(compare with Fig. 5g), numerous microtubule bundles were 
revealed in injected cells by electron microscopy (Fig. 6). At 
higher magnification the spacing between single microtubules 
in such bundles was not <20 nm (Fig. 6D). 
DISCUSSION 
We have identified and partially characterized the antigenic 
site of a-tubulin  reacting with the rat monoclonal YL  1/2 
antibody raised against yeast tubulin (9). Studies on the ability 
of YL 1/2 to bind to tyrosylated and detyrosylated a-tubulin 
indicated that the antibody reacts specifically with tyrosylated 
a-tubulin. The primary structure of the antigenic site is not 
known in complete detail but probably related to the peptide 
Gly-(Glu)3-Gly-(Gluh-Tyr. This  peptide  constitutes the  se- 
quence of the eight last amino acids of the carboxyterminus 
of tyrosylated a-tubulin (18,  28) and reacts specifically with 
YL 1/2 as shown by preabsorption experiments. 
With respect to this result it is important to note frequent 
antigenicity of the carboxyterminus of proteins and hydro- 
philic peptides (11).  Both indirect immunofluorescence and 
electron  microscopy studies  of cytoskeletons and  microtu- 
bules polymerized in vitro in the presence of YL 1/2 antibody, 
respectively, show that YL 1/2 binds to the surface of micro- 
tubules. Thus the carboxyterminus of a-tubulin is exposed on 
the microtubule surface. This location is in agreement with 
the removal of carboxyterminal tyrosine from a-tubulin in 
cytoskeletal microtubules by pancreatic carboxypeptidase A 
and  further  with  the  lack  of effect of YL  1/2  on  tubulin 
polymerization, a process requiring the interaction between 
tubulin domains presumably masked within the microtubule 
after polymerization. 
We have also observed that YL 1/2 does not interfere with 
the binding of MAP2  or tau to microtubules in vitro.  This 
result  indicates that  the  tyrosylated carboxyterminus of a- 
tubulin is not part of the microtubule binding sites for MAP2 
or tau and suggests that binding of MAP2 and tau to micro- 
tubules is not regulated by tyrosylation of a-tubulin. 
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Although YL  1/2 has no effect on microtubule polymeri- 
zation  and  stability, and  the  binding  of MAP2  and tau  to 
microtubules,  it  produces  strong  concentration-dependent 
changes in the distribution and function of microtubules when 
injected into cultured cells (see  accompanying paper, refer- 
ence  32).  It is  not  clear whether  or not  the  formation  of 
microtubule bundles in cells injected with YL 1/2 is produced 
by the cross-linking of microtubules by the  antibody.  It is 
important to  note  in  this  respect that  the  lateral  distance 
between the microtubules packed in the cell into bundles was 
not smaller than 20  nm. This distance is much larger than 
the largest distance possible between the two antigen binding 
sites of an IgG molecule (10-12 nm). Therefore it is possible 
that the binding of YL  l/2  to the  microtubule surface can 
instead interfere with  the  interaction  of microtubules with 
unknown cell components required for the normal distribu- 
tion of microtubules inside the cell. The collapse of microtu- 
bule bundles around the nucleus in cells injected with high 
concentrations of YL 1/2 could either result from formation 
of large bundles of microtubules or as indicated above from 
the antibody interfering in the interaction of other unknown 
cell  components with  the  microtubules (see  accompanying 
paper, reference 32). 
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